The Complete Cellular Energy Peptide Protocol

Your mitochondria are not failing because you lack some exotic peptide. They are failing because the system that produces energy has been degraded at multiple levels simultaneously, and adding one compound on top of that degraded system is like upgrading the exhaust system on an engine with a cracked block.

That is the logic behind a tiered protocol. You are not stacking interventions randomly. You are rebuilding a production system in the correct order.

Here is the chain you need to understand before any individual compound makes sense. Your mitochondria produce energy through a process called oxidative phosphorylation, which is essentially a series of protein complexes embedded in the inner mitochondrial membrane that pass electrons down a chain and use the released energy to pump protons and generate ATP. That membrane is not just scaffolding. It is an active participant, and its structural integrity is maintained by a lipid called cardiolipin, which anchors those protein complexes in place and keeps the whole assembly running efficiently. As you age, cardiolipin gets oxidized and damaged, the complexes drift, electron leak increases, and you generate more reactive oxygen species, which are the byproducts that cause oxidative damage, and that oxidative damage further degrades the membrane. It is a self-reinforcing cycle.

Meanwhile, your cells are running a separate accounting system for metabolic stress using a molecule called NAD+, which is the oxidized form of nicotinamide adenine dinucleotide and functions as the electron carrier that makes the whole energy chain possible in the first place. NAD+ also activates sirtuins, which are the proteins that regulate cellular repair and stress response. You produce less NAD+ as you age, partly because consumption increases and partly because the enzyme responsible for its synthesis, something called NAMPT, which is nicotinamide phosphoribosyltransferase, declines over time.

On top of this, your tissues are accumulating senescent cells, which are cells that have stopped dividing but refuse to die, and they secrete inflammatory signals that damage surrounding tissue and interfere with the mitochondria of healthy neighboring cells. That is the third degradation layer.

So the protocol is ordered around those three problems. You address the raw materials first, then the NAD+ system, then senescent cell burden, and then the mitochondrial membrane directly.

The foundation tier is exactly what it sounds like: creatine at 5 grams per day, a quality multivitamin, CoQ10, zinc, fish oil, vitamin D3 with K2, and magnesium glycinate. These are not placeholders. CoQ10 is a cofactor in the electron transport chain itself. Magnesium is required for ATP synthesis because ATP exists in cells as a magnesium-ATP complex. Zinc supports over 300 enzymatic reactions including those involved in mitochondrial function. If these are deficient, the advanced compounds have nothing to amplify.

NAD+ support comes next because restoring that electron carrier restores the signaling environment that makes mitochondrial repair possible. Injectable NAD+ at 50 to 100 milligrams subcutaneous three to five times per week is more direct than oral precursors because it bypasses the conversion steps that can become rate-limiting. But the cycling instruction here is not arbitrary. Long-term exogenous NAD+ supplementation can downregulate your body's own NAMPT production, which is the enzyme that makes NAD+ endogenously, so the 8 to 12 weeks on and 4 to 8 weeks off structure is specifically designed to prevent dependency. If you are between 35 and 45 and your own production is still competitive, oral precursors like NMN may be sufficient, and the more aggressive injectable approach can be reserved for later.

Once you are past 45 or 50, the senescent cell burden becomes a real bottleneck, and this is where Epithalon and FOXO4-DRI enter. Epithalon at 500 micrograms to 1 milligram per day for 10 to 20 days is a tetrapeptide that research suggests activates telomerase, though most of the supporting data here comes from animal models and limited human studies, so that claim deserves proportionate confidence. FOXO4-DRI works through a cleaner mechanism that is better characterized in the literature. Senescent cells survive longer than they should because they express a protein called FOXO4 that keeps them alive by activating p53, which is the tumor suppressor pathway, inside those specific cells. FOXO4-DRI is a peptide that disrupts that FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells. The preclinical data from de Keizer et al. in 2017 showed 11.73-fold selectivity for senescent cells over healthy ones. It is still preclinical, which matters, and that distinction should inform how someone weighs the risk-benefit calculation for themselves.

The core energy compounds are SS-31 and MOTS-c, and they are stackable precisely because they work at different points in the system.

SS-31, also called elamipretide, is a tetrapeptide that concentrates in the inner mitochondrial membrane through electrostatic attraction and binds to cardiolipin. By stabilizing cardiolipin, it keeps the electron transport chain complexes properly organized, reduces electron leak, and drops reactive oxygen species production by roughly 40 to 60 percent based on Szeto's 2014 mechanism work. The TAZ-POWER trial, which ran SS-31 in patients with Barth syndrome, a condition where cardiolipin synthesis is genetically impaired, showed a 96-meter improvement in 6-minute walk distance and approximately 45 percent gains in both leg strength and cardiac function over three years at 40 milligrams per day IV. The protocol dose is much lower at around 2 milligrams subcutaneous daily, and that gap between the clinical trial dose and the self-administration context is worth being transparent about.

MOTS-c is a mitochondrial-derived peptide, which means it is encoded in the mitochondrial genome rather than the nuclear genome, and it activates something called AMPK, which is AMP-activated protein kinase and functions as the cell's master energy sensor. When AMPK is active, cells shift toward more efficient fuel usage, increase glucose uptake, suppress inflammatory pathways, and reduce the oxidative stress that was degrading the cardiolipin in the first place. Lee et al. showed in 2015 that MOTS-c improved insulin sensitivity and metabolic homeostasis through this pathway, and more recent work from Gudiksen et al. published in 2026 demonstrated improvements in intrinsic mitochondrial efficiency, meaning the machinery itself runs better rather than just the cellular signaling around it. At 10 milligrams per week split across three days, you are keeping AMPK activation relatively continuous while the membrane repair work from SS-31 runs concurrently.

The tier five compounds are genuinely conditional. 5-Amino-1MQ at 50 to 100 milligrams per day inhibits an enzyme called NNMT, which is nicotinamide N-methyltransferase, and that enzyme in adipose tissue diverts NAD+ precursors away from energy metabolism. In a mouse model, NNMT inhibition produced a 35 percent reduction in body mass. But if you are already lean and metabolically healthy, that enzyme is not the problem, and blocking it accomplishes nothing meaningful. Methylene blue can accept electrons directly from NADH and pass them to cytochrome c, effectively donating electrons to the chain at a point downstream of the first complex, but it inhibits MAO enzymes in a way that creates dangerous interactions with SSRIs, and G6PD deficiency makes it unsafe at any dose. Injectable L-carnitine addresses a different bottleneck entirely: the transport of fatty acids across the inner mitochondrial membrane, and oral bioavailability is low enough that the injectable form is the one that actually changes the substrate supply.

The thing about this protocol is that it is not a list of compounds that do good things. It is a sequence. You restore the inputs, then the signaling molecule, then clear the cellular damage, then repair the membrane, then activate the efficiency pathways. Running tier four without tier one is asking a damaged factory to run better by upgrading one machine while the power supply and raw materials are still compromised.

The compounds enhance a system. They do not constitute one.

---

References

1. Thompson WR et al. TAZ-POWER trial. Genetics in Medicine. 2024;26(7):101133 — SS-31 (elamipretide) +96m on 6MWT, +45% leg strength/cardiac function over 3 years
2. Szeto HH. Mitochondria-targeted cytoprotective peptides. British Journal of Pharmacology. 2014;171:2029-2050 — SS-31 mechanism, cardiolipin binding, 40-60% ROS reduction
3. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015 — MOTS-c AMPK activation, insulin sensitivity
4. Gudiksen A et al. Free Radical Biology and Medicine. 2026;246:682-696 — MOTS-c improves intrinsic mitochondrial efficiency
5. de Keizer et al. Targeted apoptosis of senescent cells. Cell. 2017 — FOXO4-DRI senolytic mechanism, 11.73-fold selectivity
6. Khavinson et al. Epithalon telomerase activation research — limited human + animal data
7. Nkandeu et al. 5-Amino-1MQ mouse study — 35% body mass reduction, NNMT inhibition in adipose tissue

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness